The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, today announced that Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), Stemline's development partner in Japan, received Orphan Drug Designation for tagraxofusp, from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the expected indication of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Related Keywords

Japan ,United States ,Elcin Barker Ergun ,Menarini Industrie Farmaceutiche Riunite ,Stemline Therapeutics Inc ,World Health Organization ,Menarini Group ,Nippon Shinyaku ,Orphan Drug Designation ,Industrie Farmaceutiche ,Stemline Therapeutics ,Nc ,Nippon Shinyaku Co ,Td ,Hematologic Malignancy ,Mhlw ,Lasmacytoid Dendritic Cell ,Approved Treatment ,